{
  "slug": "malaria-travel",
  "question": "What are the odds of contracting malaria as a traveler to an endemic country?",
  "category": "health",
  "tags": [
    "travel"
  ],
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Malaria sits awkwardly in the traveler’s risk imagination. For some readers — the ones booking a two-week resort stay in Cancun or a Bangkok stopover — it looms as an exotic, serious, vaguely Victorian danger. For others — the ones heading to rural Nigeria without a travel clinic visit — it is a background rumor that gets waved off until fever starts. We haven’t found a rigorous recent survey that isolates “fear of catching malaria on a trip” from general travel-health anxiety, so the perceived side of this entry is marked as editorial intuition. The working prior most Likelier readers carry into planning is roughly “small but real” — which, averaged across all destinations and prep levels, is fine, but hides a range of five or six orders of magnitude underneath.\n",
    "rough_estimate": "most travelers guess somewhere in the low percent range, regardless of destination",
    "kind": "intuition"
  },
  "native": {
    "display": "~1 in 10,000 per trip (2-week Sub-Saharan Africa visit, prophylaxis taken as directed)",
    "numerator": 1,
    "denominator": 10000,
    "unit": "per traveler-trip",
    "population": "reference traveler: 2-week visit to Sub-Saharan Africa, chemoprophylaxis compliant"
  },
  "normalized": {
    "lifetime_us_adult": 0.0001,
    "display": "~1 in 10,000 per reference trip",
    "log_value": -4,
    "assumptions": "The headline figure is an order-of-magnitude estimate for a reference traveler: a 2-week leisure trip to Sub-Saharan Africa, taking a modern chemoprophylaxis regimen (atovaquone-proguanil, doxycycline, or mefloquine) as directed, using DEET and sleeping in a screened or air-conditioned room. It is NOT a lifetime figure for a US adult; malaria risk for travelers is overwhelmingly a per-trip, per-destination question, so this entry uses scope “activity_specific_lifetime” to mean “per traveler-trip.” The same itinerary without prophylaxis is roughly 50× riskier (~1 in 200). A 2-week beach trip to Mexico or a stopover in Bangkok is several orders of magnitude lower (see regional_breakdown). The uncertainty band reflects the range across prophylaxis regimens, seasons, and rural-vs-urban exposure within Sub-Saharan Africa.\n",
    "uncertainty": {
      "low": 0.00002,
      "high": 0.0005
    },
    "scope": "activity_specific_lifetime"
  },
  "sources": [
    {
      "url": "https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/malaria.html",
      "title": "Malaria — CDC Yellow Book 2024 (Health Information for International Travel)",
      "publisher": "US Centers for Disease Control and Prevention (CDC)",
      "source_type": "govt_report",
      "statistic": "Almost all ~2,000 US malaria cases per year are imported; 93% of 2019 cases with known country of acquisition came from Africa, 4% from Asia, 2% from the Caribbean and Americas, <1% from Oceania and the Middle East; 76% of US civilian cases were in travelers visiting friends and relatives.",
      "excerpt": "\"Travelers going to malaria-endemic destinations are at risk of contracting the disease. &hellip; almost all the approximately 2,000 cases of malaria that occur each year in the United States are imported. &hellip; Of cases in 2019 for which country of acquisition was known, 93% were acquired in Africa, 4% in Asia, 2% in the Caribbean and the Americas, and &lt;1% in Oceania and the Middle East. &hellip; Of U.S. civilians with malaria who reported a reason for travel, 76% were visiting friends and relatives. &hellip; No antimalarial drug is 100% protective, so travelers must combine chemoprophylaxis with mosquito avoidance and personal protective measures.\"\n",
      "source_date": "2023-05-01",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260420043128/https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/malaria.html",
      "calculation_notes": "CDC Yellow Book is the authoritative traveler-facing guidance. The 93% Africa share among US imported cases, combined with the fact that US residents take on the order of 15–20 million trips per year to malaria-endemic countries, is the basis for the regional_breakdown ordering: Sub-Saharan Africa dominates, everywhere else is a rounding error. The 76% VFR (visiting friends and relatives) share corroborates the “prophylaxis missed or stopped early” personal factor — VFR travelers historically under-use chemoprophylaxis relative to tourists. Per-trip attack rates are order-of-magnitude estimates extrapolated from Behrens and Massad travel-medicine literature: roughly 1–3% per month without prophylaxis in West Africa wet season, ~20× reduction with compliant prophylaxis.\n",
      "independence_note": "CDC Yellow Book is the primary US traveler-facing clinical guidance, synthesised from CDC NMSS surveillance and the peer-reviewed travel-medicine literature. Shares publisher (and NMSS upstream) with the CDC Malaria Surveillance source below — treat the two CDC citations as one institutional voice; the WHO World Malaria Report and the Massad/Behrens modelling paper provide the genuine independent verification.\n"
    },
    {
      "url": "https://www.cdc.gov/malaria/php/surveillance-report/index.html",
      "title": "Data and Statistics on Malaria in the United States",
      "publisher": "US Centers for Disease Control and Prevention (CDC)",
      "source_type": "govt_report",
      "statistic": "~2,000 US malaria cases reported per year; average of nearly 7 deaths per year over 2007–2022; 95% of US malaria patients did not take appropriate malaria prevention medication.",
      "excerpt": "\"Approximately 2,000 malaria cases a year are reported in the United States, and on average there were nearly 7 deaths per year for the period 2007–2022. &hellip; 95% of people with malaria did not take appropriate malaria prevention medication.\"\n",
      "source_date": "2024-01-01",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413175159/https://www.cdc.gov/malaria/php/surveillance-report/index.html",
      "calculation_notes": "CDC domestic surveillance anchors the “prophylaxis works” claim: 95% of confirmed US cases are in travelers who did not take appropriate prevention, which implies prophylaxis compliance drops risk by roughly an order of magnitude or more relative to no prevention (exact reduction varies by regimen, destination, and adherence). The ~7 deaths / ~2,000 cases ratio gives a US case-fatality rate of ~0.35% with access to wealthy-country critical care — consistent with the ~0.5% figure for treated P. falciparum in high-income health systems used in the body text.\n",
      "independence_note": "CDC Yellow Book and CDC Malaria Surveillance share CDC as publisher, but they are distinct pipelines: the Yellow Book is clinical guidance synthesized from travel-medicine literature and NMSS, while the surveillance report is the raw NMSS case and mortality count. We treat them as corroborating rather than independent.\n"
    },
    {
      "url": "https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024",
      "title": "World Malaria Report 2024",
      "publisher": "World Health Organization",
      "source_type": "reputable_reference",
      "statistic": "263 million malaria cases and 597,000 deaths worldwide in 2023; ~95% of deaths occurred in the WHO African Region.",
      "excerpt": "\"there were an estimated 263 million cases and 597 000 malaria deaths worldwide in 2023 &hellip; 11 million more cases in 2023 compared to 2022, and nearly the same number of deaths. &hellip; Approximately 95% of the deaths occurred in the WHO African Region.\"\n",
      "source_date": "2024-12-11",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413175237/https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024",
      "calculation_notes": "WHO World Malaria Report gives the global denominator: 263 million cases per year, 95% of deaths in the WHO African Region. This concentration is what drives the regional_breakdown in this entry: a 2-week trip to Sub-Saharan Africa dominates every other travel malaria risk by two to six orders of magnitude. WHO data is methodologically independent of CDC surveillance (WHO programmatic estimates vs US NMSS case reports), so this is a genuine independent corroboration of where the risk lives.\n",
      "independence_note": "WHO programmatic malaria estimates are derived from country-level case reporting and modeled adjustments, a separate pipeline from CDC’s US-facing NMSS surveillance. Independent corroboration on the “95% of deaths are in the WHO African Region” figure.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/20015392/",
      "title": "Modeling the risk of malaria for travelers to areas with stable malaria transmission",
      "publisher": "Malaria Journal / Massad E, Behrens RH, Burattini MN, Coutinho FAB",
      "source_type": "peer_reviewed",
      "statistic": "Per-trip malaria risk for non-immune travelers: ~0.2% per trip (2/1,000) for typical visit; 0.5% for stays >4 months during peak transmission",
      "excerpt": "\"The calculated risk for visitors staying longer than 4 months during peak transmission was 0.5% per visit.\"\n",
      "source_date": "2009-12-16",
      "source_accessed": "2026-04-12",
      "archive_url": "https://web.archive.org/web/20260413175320/https://pubmed.ncbi.nlm.nih.gov/20015392/",
      "calculation_notes": "This is the Behrens/Massad paper referenced in the entry's calculation_notes but not previously cited as a formal source. Provides a directly modeled per-trip attack rate for non-immune travelers, substantiating the entry's order-of-magnitude ~1 in 200 per-trip estimate.\n",
      "independence_note": "Independent of CDC Yellow Book and WHO — uses mathematical transmission modelling rather than surveillance data.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Death in a plane crash (per flight)",
      "lifetime_us_adult": 7.3e-8
    },
    {
      "label": "Death by shark attack (lifetime, US adult)",
      "lifetime_us_adult": 1.76e-7
    },
    {
      "label": "Death by lightning strike (lifetime, US adult)",
      "lifetime_us_adult": 0.00000354
    },
    {
      "label": "Mosquito-borne disease death (lifetime, global average)",
      "lifetime_us_adult": 0.00525
    }
  ],
  "regional_breakdown": [
    {
      "region": "Sub-Saharan Africa, rural, no prophylaxis, 1 month wet season",
      "probability": 0.03,
      "notes": "Order-of-magnitude estimate from travel-medicine literature. West Africa without prevention is the highest-risk itinerary a civilian traveler can take."
    },
    {
      "region": "Sub-Saharan Africa, 2 weeks, compliant prophylaxis + DEET + screens",
      "probability": 0.0001,
      "notes": "The headline reference case. Prophylaxis is not 100% protective but drops risk roughly 20×."
    },
    {
      "region": "South Asia (India, Pakistan, Bangladesh), urban, with prophylaxis",
      "probability": 0.000001,
      "notes": "Mostly P. vivax; urban transmission is low. 4% of US imported cases come from Asia, across a vastly larger traveler volume than Africa."
    },
    {
      "region": "SE Asia urban (Bangkok, Kuala Lumpur, Singapore, Ho Chi Minh City)",
      "probability": 1e-8,
      "notes": "Essentially zero. Major SE Asian cities are malaria-free; risk is limited to specific forested border zones."
    },
    {
      "region": "Caribbean and Mexican tourist zones",
      "probability": 1e-8,
      "notes": "Essentially zero in standard resort areas. Residual risk in parts of rural Haiti and a few Mexican states only."
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "Chemoprophylaxis taken as directed (atovaquone-proguanil, doxycycline, or mefloquine)",
      "multiplier": 0.05,
      "notes": "CDC: 95% of US malaria patients did not take appropriate prevention. Roughly a 20× risk reduction."
    },
    {
      "factor": "Prophylaxis missed doses or stopped before the end of the post-travel course",
      "multiplier": 3,
      "notes": "Post-travel course matters: P. falciparum has a ~1-month incubation, vivax/ovale can relapse months later."
    },
    {
      "factor": "Long-stay expat, year-round exposure in endemic area",
      "multiplier": 50,
      "notes": "Duration of exposure is the single biggest driver. A year in rural SSA without prevention is percent-level annual risk."
    },
    {
      "factor": "DEET + long-lasting insecticidal net (LLIN) + screened accommodation, on top of prophylaxis",
      "multiplier": 0.3,
      "notes": "Mosquito avoidance and prophylaxis are complementary; each adds roughly the same order of protection alone."
    },
    {
      "factor": "Visiting friends and relatives (VFR) vs leisure tourist",
      "multiplier": 5,
      "notes": "VFR travelers account for 76% of US civilian malaria cases per CDC Yellow Book, driven by lower prophylaxis uptake and longer stays in rural areas."
    }
  ],
  "short_label": "Malaria (travel)",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "acute",
  "outcome_type": "recoverable_injury",
  "valence": "negative",
  "caveats": "This entry is deliberately scoped per trip, not per lifetime, because travel malaria risk is dominated by destination and duration rather than by who you are. The headline number — ~1 in 10,000 for a 2-week Sub-Saharan Africa trip with compliant prophylaxis — is an order-of-magnitude estimate, not a precise rate. True attack rates vary by country, rural vs urban setting, season, local transmission intensity, drug resistance patterns, and prophylaxis regimen. Off-prophylaxis risk in wet-season rural West Africa is percent-level per month and genuinely dangerous; risk in tourist Mexico or urban SE Asia is effectively zero. P. falciparum, dominant in SSA, has a case-fatality rate of roughly 5–10% untreated and ~0.5% with prompt treatment in a wealthy-country hospital; diagnostic delay in non-endemic emergency rooms is a documented problem, so post-travel fever within the weeks or months after an endemic trip should be evaluated for malaria even if symptoms look flu-like. This entry covers probability of infection; the sibling entry `mosquito-borne-disease` covers mortality aggregated across all mosquito-borne diseases globally.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 4,
    "d4": 5,
    "d5": 5,
    "d6": 4,
    "d7": 4,
    "d8": 5,
    "avg": 4.625,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "likelier-phase-5-agent",
  "last_reviewed": "2026-04-11",
  "reviewed": true,
  "generated_at": "2026-04-11",
  "image": {
    "alt": "A single small stylized pill capsule resting beside a folded paper passport silhouette on a pale neutral background, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/malaria-travel"
}